First Time Loading...

HOOKIPA Pharma Inc
NASDAQ:HOOK

Watchlist Manager
HOOKIPA Pharma Inc Logo
HOOKIPA Pharma Inc
NASDAQ:HOOK
Watchlist
Price: 0.8129 USD 0.23% Market Closed
Updated: May 17, 2024

Intrinsic Value

HOOK's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's i... [ Read More ]

The intrinsic value of one HOOK stock under the Base Case scenario is 0.3073 USD. Compared to the current market price of 0.8129 USD, HOOKIPA Pharma Inc is Overvalued by 62%.

Key Points:
HOOK Intrinsic Value
Base Case
0.3073 USD
Overvaluation 62%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
HOOKIPA Pharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling HOOK stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
HOOKIPA Pharma Inc

Provide an overview of the primary business activities
of HOOKIPA Pharma Inc.

What unique competitive advantages
does HOOKIPA Pharma Inc hold over its rivals?

What risks and challenges
does HOOKIPA Pharma Inc face in the near future?

Has there been any significant insider trading activity
in HOOKIPA Pharma Inc recently?

Summarize the latest earnings call
of HOOKIPA Pharma Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for HOOKIPA Pharma Inc.

Provide P/S
for HOOKIPA Pharma Inc.

Provide P/E
for HOOKIPA Pharma Inc.

Provide P/OCF
for HOOKIPA Pharma Inc.

Provide P/FCFE
for HOOKIPA Pharma Inc.

Provide P/B
for HOOKIPA Pharma Inc.

Provide EV/S
for HOOKIPA Pharma Inc.

Provide EV/GP
for HOOKIPA Pharma Inc.

Provide EV/EBITDA
for HOOKIPA Pharma Inc.

Provide EV/EBIT
for HOOKIPA Pharma Inc.

Provide EV/OCF
for HOOKIPA Pharma Inc.

Provide EV/FCFF
for HOOKIPA Pharma Inc.

Provide EV/IC
for HOOKIPA Pharma Inc.

Show me price targets
for HOOKIPA Pharma Inc made by professional analysts.

What are the Revenue projections
for HOOKIPA Pharma Inc?

How accurate were the past Revenue estimates
for HOOKIPA Pharma Inc?

What are the Net Income projections
for HOOKIPA Pharma Inc?

How accurate were the past Net Income estimates
for HOOKIPA Pharma Inc?

What are the EPS projections
for HOOKIPA Pharma Inc?

How accurate were the past EPS estimates
for HOOKIPA Pharma Inc?

What are the EBIT projections
for HOOKIPA Pharma Inc?

How accurate were the past EBIT estimates
for HOOKIPA Pharma Inc?

Compare the revenue forecasts
for HOOKIPA Pharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of HOOKIPA Pharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of HOOKIPA Pharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of HOOKIPA Pharma Inc compared to its peers.

Compare the P/E ratios
of HOOKIPA Pharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing HOOKIPA Pharma Inc with its peers.

Analyze the financial leverage
of HOOKIPA Pharma Inc compared to its main competitors.

Show all profitability ratios
for HOOKIPA Pharma Inc.

Provide ROE
for HOOKIPA Pharma Inc.

Provide ROA
for HOOKIPA Pharma Inc.

Provide ROIC
for HOOKIPA Pharma Inc.

Provide ROCE
for HOOKIPA Pharma Inc.

Provide Gross Margin
for HOOKIPA Pharma Inc.

Provide Operating Margin
for HOOKIPA Pharma Inc.

Provide Net Margin
for HOOKIPA Pharma Inc.

Provide FCF Margin
for HOOKIPA Pharma Inc.

Show all solvency ratios
for HOOKIPA Pharma Inc.

Provide D/E Ratio
for HOOKIPA Pharma Inc.

Provide D/A Ratio
for HOOKIPA Pharma Inc.

Provide Interest Coverage Ratio
for HOOKIPA Pharma Inc.

Provide Altman Z-Score Ratio
for HOOKIPA Pharma Inc.

Provide Quick Ratio
for HOOKIPA Pharma Inc.

Provide Current Ratio
for HOOKIPA Pharma Inc.

Provide Cash Ratio
for HOOKIPA Pharma Inc.

What is the historical Revenue growth
over the last 5 years for HOOKIPA Pharma Inc?

What is the historical Net Income growth
over the last 5 years for HOOKIPA Pharma Inc?

What is the current Free Cash Flow
of HOOKIPA Pharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for HOOKIPA Pharma Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
HOOKIPA Pharma Inc

Current Assets 132.7m
Cash & Short-Term Investments 92.8m
Receivables 30.8m
Other Current Assets 9.2m
Non-Current Assets 13.2m
PP&E 12.3m
Other Non-Current Assets 864k
Current Liabilities 29.5m
Accounts Payable 11.2m
Accrued Liabilities 11.6m
Other Current Liabilities 6.8m
Non-Current Liabilities 11.8m
Other Non-Current Liabilities 11.8m
Efficiency

Earnings Waterfall
HOOKIPA Pharma Inc

Revenue
53.6m USD
Operating Expenses
-103.5m USD
Operating Income
-49.9m USD
Other Expenses
2.4m USD
Net Income
-47.5m USD

Free Cash Flow Analysis
HOOKIPA Pharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

HOOK Profitability Score
Profitability Due Diligence

HOOKIPA Pharma Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Declining ROE
22/100
Profitability
Score

HOOKIPA Pharma Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

HOOK Solvency Score
Solvency Due Diligence

HOOKIPA Pharma Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
48/100
Solvency
Score

HOOKIPA Pharma Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HOOK Price Targets Summary
HOOKIPA Pharma Inc

Wall Street analysts forecast HOOK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HOOK is 4.42 USD with a low forecast of 3.03 USD and a high forecast of 5.25 USD.

Lowest
Price Target
3.03 USD
273% Upside
Average
Price Target
4.42 USD
444% Upside
Highest
Price Target
5.25 USD
546% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
HOOKIPA Pharma Inc

Ownership

HOOK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

HOOK Price
HOOKIPA Pharma Inc

1M 1M
+7%
6M 6M
+57%
1Y 1Y
-45%
3Y 3Y
-96%
5Y 5Y
-93%
10Y 10Y
-94%
Annual Price Range
0.8129
52w Low
0.421
52w High
1.52
Price Metrics
Average Annual Return -37.48%
Standard Deviation of Annual Returns 41.08%
Max Drawdown -98%
Shares Statistics
Market Capitalization 80.4m USD
Shares Outstanding 98 950 100
Percentage of Shares Shorted 0.83%

HOOK Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

HOOKIPA Pharma Inc Logo
HOOKIPA Pharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

80.4m USD

Dividend Yield

0%

Description

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.

Contact

NEW YORK
New York City
430 East 29Th Street, 14Th Floor
+114318906360.0
https://www.hookipapharma.com/

IPO

2019-04-18

Employees

131

Officers

CEO & Director
Mr. Joern Aldag
CFO & Director
Dr. Reinhard Kandera Ph.D.
Co-Founder
Mr. Lukas Flatz
Chief Operations Officer
Dr. Roman Necina Ph.D.
Chief Scientific Officer
Dr. Klaus Orlinger Ph.D.
Executive Director of Investor Relations
Mr. Matthew L. S. Beck
Show More
Executive Director of Communications
Mr. Michael Szumera
Chief Development Officer
Dr. Mark Winderlich Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one HOOK stock?

The intrinsic value of one HOOK stock under the Base Case scenario is 0.3073 USD.

Is HOOK stock undervalued or overvalued?

Compared to the current market price of 0.8129 USD, HOOKIPA Pharma Inc is Overvalued by 62%.